{
    "clinical_study": {
        "@rank": "72241", 
        "arm_group": {
            "arm_group_label": "TDM-1", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Patients with metastatic breast cancer considered HER2 negative are included are screened\n      for HER2-amplified circulating tumor cells. If at least HER2-amplified circulating tumor\n      cell is detected, patients are treated by T-DM 1 in a single ar phase II with an adaptive\n      design."
        }, 
        "brief_title": "Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Bresat Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.", 
        "condition": "Patients With Metastatic Breast Cancer Considered HER2 Negative on Primary Tumor.", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplastic Cells, Circulating"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Inclusion criteria for screening:\n\n          -  Breast adenocarcinoma considered HER2-negative on the primary tumour\n\n          -  A least one metastatic site and/or inoperable loco-regional relapse\n\n          -  Measurable disease (RECIST v1.1)\n\n          -  Age from 18 to 75 years\n\n          -  Performance status of 0-1\n\n          -  Efficient contraceptive in non-menopaused women\n\n        Inclusion criteria for treatment :\n\n          -  At least 1 (Cohort \" L \") or 5 (cohort \" H \") HER2 amplified CTC\n\n          -  Adequate cardiac function\n\n          -  Adequate hematological and biochemical blood tests\n\n        Exclusion Criteria:\n\n          -  Life expectancy of less than 3 months\n\n          -  Previous history of any other stage III or IV invasive cancer\n\n          -  Male breast cancer\n\n          -  Uncontrolled brain metastases\n\n          -  Significant cumulated exposure to anthracyclins\n\n          -  Current or previous significant history of cardio-vascular/pulmonary disease\n\n          -  Previous use of trastuzumab"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "480", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975142", 
            "org_study_id": "IC 2013-03"
        }, 
        "intervention": {
            "arm_group_label": "TDM-1", 
            "intervention_name": "Trastuzumab - Emtansine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Trastuzumab", 
                "Maytansine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic breast cancer", 
            "Primary tumor HER2 negative", 
            "CTC HER2 positive"
        ], 
        "lastchanged_date": "November 14, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "V\u00e9ronique SERVENT, DR"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59020"
                    }, 
                    "name": "Centre Oscar Lambret"
                }, 
                "investigator": {
                    "last_name": "V\u00e9ronique SERVENT, DR", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nicole TUBIANA-MATHIEU, DR"
                }, 
                "facility": {
                    "address": {
                        "city": "Limoges", 
                        "country": "France", 
                        "zip": "87042"
                    }, 
                    "name": "Chu de Limoges"
                }, 
                "investigator": {
                    "last_name": "Nicole TUBIANA-MATHIEU, dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gilles ROMIEU, DR"
                }, 
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34298"
                    }, 
                    "name": "Centre Val d'Aurelle - P. Lamarque"
                }, 
                "investigator": {
                    "last_name": "Gilles ROMIEU, DR", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "francois-clement.bidard@curie.fr", 
                    "last_name": "Fran\u00e7ois-Cl\u00e9ment BIDARD, DR"
                }, 
                "facility": {
                    "address": {
                        "city": "Pars", 
                        "country": "France", 
                        "zip": "75005"
                    }, 
                    "name": "Institut Curie"
                }, 
                "investigator": {
                    "last_name": "Fran\u00e7ois-Cl\u00e9ment BIDARD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Florence LEREBOURS, DR"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint-cloud", 
                        "country": "France", 
                        "zip": "SAINT-CLOUD"
                    }, 
                    "name": "Institut Curie - H\u00f4pital Ren\u00e9 HUGENIN"
                }, 
                "investigator": {
                    "last_name": "Florence LEREBOURS, DR", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Alain LORTHOLARY, DR"
                }, 
                "facility": {
                    "address": {
                        "city": "Vandoeuvre Les Nancy", 
                        "country": "France", 
                        "zip": "54519"
                    }, 
                    "name": "Centre Catherine de Sienne"
                }, 
                "investigator": {
                    "last_name": "Alain LORTHOLARY, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Elisabeth LUPORSI, DR"
                }, 
                "facility": {
                    "address": {
                        "city": "Vandoeuvre Les Nancy", 
                        "country": "France", 
                        "zip": "54519"
                    }, 
                    "name": "Institut de Canc\u00e9rologie de Lorraine"
                }, 
                "investigator": {
                    "last_name": "Elisabeht LUPORSI, DR", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Bresat Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.", 
        "overall_contact": {
            "email": "emmanuelle.bouffier@curie.fr", 
            "last_name": "Patricia TRESCA, MD", 
            "phone": "+33156245765"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment every 6 weeks.", 
            "measure": "Tumor response rate to T-DM1 in patients with HER2 amplified circulating tumor cells", 
            "time_frame": "Until disease progression (estimated duration : 1 year)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975142"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Detection rate of HER2 amplified circulating tumor cells, heterogeneity rate between circulating tumor cells and correlations with patient characteristics", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Technical failure rate and reproducibility of HER2 FISH on circulating tumor cells", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Correlation between HER2 FISH and immunofluorescence on circulating tumor cells", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Progression-free survival", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Disease control rate (responses and stable diseases)", 
                "time_frame": "Until disease progression (estimated duration : 1 year)"
            }, 
            {
                "measure": "Correlation between treatment efficacy and HER2 FISH results (level of amplification, absolute number and percentage of amplified cells)", 
                "time_frame": "Until disease progression (estimated duration : 1 year)"
            }, 
            {
                "measure": "Changes in CTC numbers during treatment", 
                "time_frame": "Until disease progression (estimated duration : 1 year)"
            }, 
            {
                "measure": "Circulating tumor DNA before and during treatment", 
                "time_frame": "Until disease progression (estimated duration : 1 year)"
            }, 
            {
                "measure": "Toxicity", 
                "time_frame": "Until disease progression (estimated duration : 1 year)"
            }
        ], 
        "source": "Institut Curie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut Curie", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}